Introduction
The growth and dierentiation of hematopoietic progenitor cells are regulated by hematopoietic cytokines, including erythropoietin (Epo) and interleukin (IL)-3. The receptors for Epo (EpoR) and Il-3 mainly couple with a member of the JAK family of tyrosine kinases, Jak2, which phosphorylates the receptors and thereby recruits various signaling molecules mainly through interaction between the tyrosine phosphorylated docking sites in the receptors and the SH2 domains in the signaling molecules (Ihle, 1995) . The small GTPase Ras, which is inactive in the GDPbound form, is then activated by the exchange of GDP for GTP, a reaction which is catalyzed by guanine nucleotide exchange factors (GEFs) recruited to the activated cytokine receptors (Bar-Sagi and Hall, 2000; Takai et al., 2001) . For instance, the adaptor protein Grb2, which forms a complex with the Ras GEF Sos1, is recruited directly or indirectly through induced interaction with Shc to the activated cytokine receptors and thereby brings Sos1 to the vicinity of Ras (Ihle, 1995; Miura et al., 1994c) . Similarly, the adaptor protein CrkL plays a role in cytokine activation of Ras and the Ras family GTPase Rap1 by recruiting the Ras GEF C3G to the activated receptors for Epo and IL-3 (Arai et al., 2001a,b; Nosaka et al., 1999) . The activated, GTP-bound form of Ras then activates the Raf/MEK/Erk signaling cascade leading to the activation of a transcription factor, Elk-1, which enhances transcription of growth-related proteins, such as c-Fos, through the serum response element. The activated form of Ras also binds the p110 catalytic subunit of phosphatidylinositol 3'-kinase (PI3K) and activates its catalytic activity. PI3K is also recruited to the tyrosine phosphorylated cytokine receptors, including the EpoR (Damen et al., 1995; Miura et al., 1994b) , via the SH2 domain in the regulatory p85 subunit and activated through this interaction. A serine/threonine kinase, Akt, is activated downstream of PI3K and phosphorylates various signaling molecules, including Bad and FKHR, to promote cell survival (Vanhaesebroeck and Alessi, 2000) .
The Rho family GTPases, including Rho, Rac, and Cdc42, regulate a wide spectrum of cellular functions, including cytoskeletal organization, transcription, cell growth, development, and superoxide production (BarSagi and Hall, 2000; Bishop and Hall, 2000; Takai et al., 2001; Van Aelst and D'Souza-Schorey, 1997) . Similar to Ras, Rho GTPases alternate between GDP-and GTP-bound states and function as intermediary switches to mediate signals from receptors and their associated kinases to downstream eectors. The Rac subfamily of Rho GTPases has three highly homologous members, Rac (Rac1), Rac2, and Rac3. Unlike Rac and Rac3, which are widely expressed, Rac2 is found only in hematopoietic cells and functions as an essential regulator of neutrophil chemotaxis, Lselectin capture and rolling, and superoxide production. In ®broblasts, Rac plays a role in cytoskeletal rearrangement in growth factor-stimulated cells, leading to the formation of lamellipodia. Rac is also involved in transcription and growth control and in Ras-induced transformation in ®broblasts. The Rac eector serine/threonine kinases, PAKs, have been implicated in mediating some of these functions of Rac (Bar-Sagi and Hall, 2000; Bishop and Hall, 2000; Takai et al., 2001; Van Aelst and D'Souza-Schorey, 1997) . It has recently been reported that PAK1 is activated by IL-3 and plays a role in anti-apoptotic signaling in IL-3-dependent FL5.12 cells (Schurmann et al., 2000) . Furthermore, in IL-3-dependent murine hematopoietic BaF3 cells, a constitutively activated Rac mutant, Rac12V, was shown to render the cells resistant to apoptosis upon IL-3 deprivation (Nishida et al., 1999) . These observations implicate Rac in cytokine-receptor signaling and in regulation of growth of hematopoietic cells. However, it has remained to be determined whether hematopoietic cytokines, including Epo and IL-3, activate Rac in hematopoietic cells. Using a model hematopoietic progenitor cell line, 32D/ EpoR-Wt, we demonstrate in the present study that Rac is very rapidly and transiently activated upon Epo or IL-3 stimulation at downstream of the Ras/PI3K pathway and plays a role in regulation of Erk activation.
Results

Epo or IL-3 stimulation induces Rac activation in hematopoietic cells
To explore the possibility that Rac may be involved in signaling from receptors for Epo and IL-3, we ®rst examined whether Epo or IL-3 induces Rac activation in 32D/EpoR-Wt cells, a clone of murine IL-3-dependent 32D cells stably expressing the transfected EpoR. After cytokine stimulation, cells were lysed and Rac-GTP was anity puri®ed by using the GST-PAK2-RBD fusion protein as described under Experimental Procedures. As shown in Figure 1a ,b, anti-Rac immunoblotting of the GST-PAK2-RBD precipitates revealed that Rac was very rapidly and transiently activated by stimulation with Epo or IL-3 in 32D/ EpoR-Wt cells; the Rac activation peaked within 1 min after stimulation and declined thereafter. It was further demonstrated that activation of Rac was detectable when cells were stimulated with as low as 1 U/ml Epo or with 0.1 ng/ml IL-3 and dose-dependently increased when cells were stimulated with higher concentrations of these cytokines (Figure 1c,d ). Anti-Rac blotting of total cell lysates showed that the total amount of Rac in cells did not change signi®cantly after stimulation with IL-3 or Epo (Figure 1, lower panels) . The antiRac antibody used for immunoblotting recognizes both Rac (Rac1) and Rac2. However, in repeated experiments, we failed to detect any signi®cant activation of Rac2 using antibody speci®c for Rac2 (negative data not shown). These results indicate that Rac is activated by Epo or IL-3 stimulation in a time-and dosedependent manner in 32D/EpoR-Wt cells.
To rule out the possibility that the cytokine-induced Rac activation is observed uniquely in 32D/EpoR-Wt cells, we next examined a human leukemic cell line, UT-7, which expresses the endogenous EpoR and proliferates in response to Epo. As shown in Figure 1e , Epo induced a very rapid and transient Rac activation, which is comparable with that observed in 32D/EpoRWt cells.
Involvement of CrkL, C3G, and Ras in Epo-or IL-3-induced activation of Rac
We previously demonstrated that the adaptor protein CrkL is involved in Epo-or IL-3-induced activation of Ras and Rap1 through its interaction with C3G, a GEF for the Ras family GTPases (Arai et al., 2001b; Nosaka et al., 1999) . Because the Crk family of adaptor proteins has also been implicated in Rac activation (Kiyokawa et al., 1998) , we next examined the Rac activation in a clone of 32D/EpoR-Wt cells, 32DE/Tet-CrkL, that inducibly overexpresses CrkL when withdrawn from tetracycline. As shown in Figure  2a ,b, the cytokine-stimulated as well as basal level of Rac-GTP in 32DE/Tet-CrkL was augmented when cells were depleted overnight from tetracycline. AntiRac and anti-CrkL blotting of total cell lysates con®rmed that the depletion of tetracycline increased the expression level of CrkL but not that of Rac in 32DE/Tet-CrkL cells. These results implicate CrkL in Epo-and IL-3-induced activation of Rac.
A possible involvement of C3G, which forms a complex with CrkL, was next examined by using 32DE/Tet-C3G cells that overexpress C3G when withdrawn from tetracycline. The cells inducibly overexpressing C3G also exhibited the augmented levels of the basal and cytokine-induced Rac activity ( Figure  2c,d) , although the augmentation induced by C3G overexpression was less than that induced by CrkL overexpression, which may be due to the fact that the increase in expression of C3G in 32DE/Tet-C3G cells was less signi®cant than that of CrkL in 32DE/TetCrkL cells. It is therefore suggested that C3G may also be involved in Rac activation, most likely at downstream of CrkL.
To explore the possibility that Ras, which is activated downstream of CrkL and C3G in cytokine-receptor signaling, may be involved in activation of Rac, we next examined 32DE/Tet-Ras61L and 32DE/Tet-Ras17N cells, clones of 32D/EpoR-Wt that inducibly express activated and dominant negative mutants of H-Ras, respectively, when withdrawn from tetracycline. Anti-Ras blotting of precipitates obtained from cell lysates using the GST-Raf-RBD fusion protein con®rmed that the constitutively activated mutant of Ras, which migrated faster than cytokine-activated endogenous Ras, is inducibly expressed in 32DE/Tet-Ras61L cells withdrawn from tetracycline ( Figure 3a) and that the cytokine-induced activation of endogenous Ras is signi®cantly inhibited in 32DE/Tet-Ras17N cells withdrawn from tetracycline ( Figure 3b ). The Epo-induced Rac activation was augmented and sustained in cells inducibly expressing the activated Ras mutant (Figure 3c ), while it was signi®cantly diminished in cells inducibly expressing the dominant negative Ras mutant (Figure 3d ). The IL-3-induced activation of Rac was similarly enhanced or diminished by the induced expression of Ras61L or Ras17N, respectively, in these cells (data not shown). These data indicate that the cytokine-induced activation of Rac is dependent on the Ras activation.
The Epo-induced activation of Erk and Akt, as detected by immunoblotting with antibodies speci®c for activated forms of these kinases, was also augmented or inhibited in cells inducibly expressing the activated or dominant negative Ras mutant, respectively ( Figure  3c ,d, lower panels). Because Akt is activated downstream of PI3K, these results are in agreement with the idea that the Epo-induced activation of PI3K as well as Erk is dependent on the Ras activation.
Cytokine-induced activation of Rac is dependent on PI3K and involved in activation of Erk
To examine whether PI3K, activated downstream of Ras, is involved in cytokine-induced Rac activation, we next analysed the cytokine-induced Rac activation in 32D/EpoR-Wt cells pretreatment with the PI3K inhibitor LY294002. As demonstrated in Figure 4 , the Rac activation induced by Epo as well as by IL-3 was signi®cantly inhibited by LY294002, which indicates that PI3K is involved in Rac activation. Intriguingly, however, LY294002 did not inhibit but rather slightly increased the basal Rac activity, which suggests that the basal activity of PI3K is not required for that of Rac. The activation of Akt was abrogated by LY294002, which is in agreement with the notion that Akt is activated downstream of PI3K. Interestingly, a signi®cant inhibitory eect of LY294002 on the Erk activation was observed at 1 min after stimulation with Epo or IL-3 ( Figure 4 , bottom panels), which is in accordance with a very recent report that expression of Figure 1 Epo as well as IL-3 activates Rac in 32D/EpoR-Wt cells. (a ± d) 32D/EpoR-Wt cells, a clone of IL-3-dependent 32D cell line expressing the EpoR, were starved from Epo overnight in serum-free medium and stimulated with Epo (10 U/ml) or IL-3 (1 ng/ ml) for indicated times in (a) or (b) respectively, or stimulated with indicated concentrations of Epo (U/ml) or IL-3 (ng/ml) for 1 min in (c) or (d) respectively. Activated Rac (Rac-GTP) was anity precipitated from cell lysates by using a GST-PAK2-RBD fusion protein, as described under Materials and methods. Eluates from the precipitates (upper panels) or total cell lysates (lower panels) were subsequently subjected to immunoblotting with anti-Rac antibody. (e) UT-7 cells, a human leukemic cell line expressing the endogenous EpoR, were starved from Epo overnight in serum-free medium and stimulated with Epo (10 U/ml) for indicated times and subjected to the Rac activation assay a dominant negative mutant of p85 or incubation with LY294002 inhibited most signi®cantly the initial phase of IL-3-induced Erk activation in BaF3 cells (Craddock et al., 2001) . Taking into consideration the fact that Rac is very rapidly activated after cytokine stimulation, the inhibitory eect of LY294002 on the very early phase of Erk raises a possibility that Rac may play a role in activation of Erk after cytokine stimulation.
To address the possible involvement of Rac in cytokine activation of Erk, we ®rst examined the eect of a dominant negative mutant of Rac, Rac17N, on Erk activation in 32D/EpoR-Wt cells transiently expressing HA-tagged Erk. Anti-phosphotyrosine immunoblotting of anti-HA immunoprecipitates demonstrated that Rac17N drastically inhibited Erk activation by Epo (Figure 5a ) as well as IL-3 (data not shown). In accordance with this, Rac17N also signi®cantly inhibited Epo-or IL-3-induced activation of Elk-1, a transcription factor activated mainly by the Ras/Erk signaling pathway ( Figure 5b ). These results indicate that Rac plays a signi®cant role in Epo-as well as IL-3-induced stimulation of the signaling pathway leading to activation of Erk and Elk-1. However, coexpression of a constitutively activated Rac mutant, Rac12V, did not induce constitutive activation of HA-Erk (Figure 5a ), thus suggesting that Rac activation alone is not sucient for the activation of Erk.
To con®rm that Rac plays a role downstream of Ras to activate the Erk/Elk-1 signaling pathway, we next examined the eect of Rac17N on Ras activation of Elk-1. As shown in Figure 5c , activation of Elk-1 induced by constitutively activated Ras61L was partially inhibited either by Rac17N or by a dominant negative mutant of Raf-1, Raf-dSE, and was drastically inhibited by coexpression of both of these dominant negative mutants. These results indicate that Rac as well as Raf-1 mediates Ras activation of the signal transduction pathway leading to Elk-1 activation.
Akt plays a negative regulatory role in cytokine-induced activation of Erk/Elk-1
To explore the possible involvement of Akt, which is activated downstream of PI3K, in cytokine-induced activation of Erk/Elk-1, we next examined the eect of myr-Akt, an activated Akt mutant, on Erk activation. As shown in Figure 6a , immunoblotting of total cell lysates with anti-phospho-Erk demonstrated that Epoinduced activation of Erk was signi®cantly impaired in a 32D/EpoR-Wt clone, 32DE/Akt-myr, expressing myr-Akt, as compared with 32D/EpoR-Wt. Reprobing ), which overexpresses CrkL or C3G when withdrawn from tetracycline, was starved from Epo overnight in serum-free medium containing 200 ng/ml tetracycline (Tet+) or without tetracycline (Tet-), as indicated. Cells were then stimulated with 10 U/ml Epo (a) and (c) or with 1 ng/ml IL-3 (b) and (d) for indicated times and subjected to the Rac activation assays. Eluates from the GST-PAK2-RBD precipitates (top panels) or total cell lysates (lower panels) were subsequently subjected to immunoblotting with anti-Rac, anti-CrkL, or anti-C3G antibody, as indicated with anti-Erk showed that the expression levels of Erk are comparable in these two cell lines, while reprobing with anti-Akt con®rmed the expression of myr-Akt, which migrates more slowly as compared with wildtype Akt, in 32DE/Akt-myr cells. We also examined 32DE/Tet-Akt-KM cells, which inducibly express a dominant negative Akt mutant, Akt-K179M, when withdrawn from tetracycline. As shown in Figure 6b , anti-phospho-Erk immunoblotting of total cell lysates showed that Epo-induced activation of Erk was cells, a clone of 32D/EpoR-Wt which expresses an activated or dominant negative form of H-Ras, respectively, when withdrawn from tetracycline, were starved from Epo overnight in serum-free medium containing 200 ng/ml tetracycline (Tet+) or without tetracycline (Tet-), as indicated. Cells were then stimulated with IL-3 (1 ng/ml) for 5 min before solubilization. Activated Ras (Ras-GTP) was anity precipitated from cell lysates by using a GST-Raf-RBD fusion protein, as described under Materials and methods, and detected by anti-Ras immunoblotting. (c,d) 32DE/Tet-Ras61L (c) or 32DE/Tet-Ras17N (d) cells were starved from Epo overnight in serum-free medium containing 200 ng/ml tetracycline (Tet+) or without tetracycline (Tet-), as indicated. Cells were then stimulated with Epo (10 U/ml) for indicated times and subjected to the Rac activation assays. Eluates from the GST-PAK2-RBD precipitates (top panels) or total cell lysates (lower panels) were subsequently subjected to immunoblotting with anti-Rac followed by reprobing with anti-Ras, anti-phospho-Erk and anti-phospho-Akt, as indicated. The positions of the Ras mutants are indicated with asterisks Figure 4 Activation of Rac is dependent on PI3K. 32D/EpoR-Wt cells were starved from Epo overnight in serum-free medium and incubated with DMSO (0.1%) or LY294002 (50 mM) for 30 min at 378C. Cells were then stimulated with 1 ng/ml IL-3 (a) or 10 U/ml Epo (b) for indicated times and subjected to the Rac activation assays. Eluates from the GST-PAK2-RBD precipitates (top panels) or total cell lysates (lower panels) were subsequently subjected to immunoblotting with anti-Rac followed by reprobing with anti-phospho-Akt and anti-phospho-Erk, as indicated signi®cantly enhanced when the expression of Akt-K179M was induced, as demonstrated by reprobing with anti-Akt, by withdrawal of cells from tetracycline. The expression level of Erk was not signi®cantly changed by withdrawal of cells from tetracycline. These data suggest that Akt plays a negative role in Epo-induced activation of Erk in 32D cells.
To con®rm that Akt plays a negative regulatory role in Epo-induced activation of Erk, we next examined the eects of myr-Akt and Akt-K179M on cytokineinduced activation of Elk-1. As shown in Figure 6c , the transient expression of myr-Akt or Akt-K179M signi®cantly inhibited or enhanced, respectively, the Epo-induced activation of Elk-1. Similarly, the IL-3-induced activation of Elk-1 was inhibited or enhanced by the transient expression of myr-Akt or Akt-K179M, respectively (data not shown). These eects of Akt mutants on Elk-1 activation are in agreement with those on Erk activation (Figure 6a,b) and, together, strongly support the idea that Akt plays an inhibitory role in cytokine-induced activation of the Erk/Elk-1 signaling pathway.
Discussion
In the present study, we have demonstrated that Epo as well as IL-3 very rapidly and transiently activates Rac in hematopoietic cells (Figure 1) . The cytokineinduced activation of Rac was enhanced in cells inducibly overexpressing CrkL or C3G, signaling molecules involved in cytokine-induced activation of the Ras/Erk signaling pathway (Figure 2 ). In addition, the cytokine-induced activation of Rac was augmented in cells inducibly expressing the activated mutant Ras61L and was decreased in those expressing the dominant negative mutant Ras17N, thus indicating that Rac is activated downstream of Ras (Figure 3) . Furthermore, the cytokine-induced activation of Rac as signi®cantly inhibited by the PI3K inhibitor LY294002 (Figure 4) . These results indicate that Epo as well as IL-3 activates Rac at least partly through the Ras/ PI3K signaling pathway. The present study has also indicated that the cytokine-induced activation of Rac may play an important role in activation of the Erk/ Elk-1 signaling pathway downstream of Ras, because the dominant negative mutant of Rac as well as that of Raf-1 signi®cantly inhibited the cytokine-induced activation of Erk as well as Elk-1 (Figure 5 ). On the other hand, Akt, which is also activated downstream of PI3K, was demonstrated to play an inhibitory role in cytokine-induced activation of Erk/Elk-1, because the activated or dominant negative Akt mutant inhibited or enhanced, respectively, the cytokine-induced activa- Figure 5 Rac is involved in activation of the Erk/Elk-1 signaling pathway. (a) 32D/EpoR-Wt cells were transfected with 25 mg of pSR-myc-RacN17 (Rac17N), pSR-myc-RacV12 (Rac12V), or an empty vector (C), as indicated, along with 20 mg of S3H-ERK2. After overnight starvation, cells were stimulated with 100 U/ml Epo for indicated times and solubilized. Transfected HA-ERK2 was immunoprecipitated with anti-HA and subjected to antiphosphotyrosine (aPY) immunoblotting followed by reprobing with anti-HA and subjected to anti-phosphotyrosine (aPY) immunoblotting followed by reprobing with anti-HA (aHA). (b) 32D/EpoR-Wt cells were transiently transfected with 25 mg of pSR-myc-RacN17 (Rac17N) or an empty vector (C), as indicated, along with 0.01 mg of pRL-SV40, 2 mg of pFA-Elk-1, and 20 mg of pFR-Luc. After overnight starvation, cells were incubated for 5 h in medium supplemented with 10 U/ml of Epo (Epo) or 2 ng/ ml of IL-3 (IL-3), or left untreated with cytokines (7), as indicated, and harvested for the dual-luciferse assay. The data represent averages+standard deviations of three independent experiments. (c) 32D/EpoR-Wt cells were transiently transfected with pcDNA-Ras61L (2 mg), pcDNA-Raf-dSE (20 mg), or pSRmyc-RacN17 (20 mg), as indicated, along with 0.01 mg of pRL-SV40, 2 mg of pFA-Elk-1, and 20 mg of pFR-Luc. The total amount of plasmids for each transfection was adjusted to become equal by adding empty vector. After overnight starvation from Epo, cells were harvested for the dual-luciferase assay tion of Erk and Elk-1 (Figure 6 ). Together, these results support a model in which Rac and Akt act downstream of PI3K to play enhancing and inhibitory roles, respectively, in regulation of the Raf/Erk signaling pathway downstream of Ras activated by the Epo or IL-3 receptor (Figure 7) .
The GEF that activates Rac in cytokine-stimulated cells has remained to be determined. However, we speculate that the Epo-or IL-3-induced activation of Rac is most likely mediated through Vav (Bustelo, 2000) , a Rac GEF speci®cally expressed in hematopoietic cells, because we and others have previously reported that Vav undergoes tyrosine phosphorylation, which activates the GEF activity of Vav (Crespo et al., 1997) , after Epo or IL-3 stimulation (Matsuguchi et al., 1995; Miura et al., 1994a) . In addition, the GEF activity of the DH domain of Vav has been shown to be regulated by the binding of PI3K products to the neighboring PH domain of Vav (Han et al., 1998) . This is in agreement with our observation that the cytokine-induced activation of Rac is at least partly dependent on PI3K. Alternatively, Rac may be activated in Epo-or IL-3-stimulated cells through Sos1, the GEF involved in Ras activation, because it has been reported that Ras activates the DH/PH domain of Sos1 through PI3K, thus leading to Rac activation (Nimnual et al., 1998) . This is also in agreement with our observation that the cytokine-induced activation of Rac is at least partly dependent on Ras and PI3K. Because the cytokine-induced activation of Rac was enhanced in cells overexpressing CrkL (Figure 2a,b) , it should be mentioned that DOCK180, a major Crk-binding protein (Hasegawa et al., 1996) , has been reported to play an important role in Rac activation mediated through Crk, a homologue of CrkL, in adherent cells (Kiyokawa et al., 1998) . Although DOCK180 is not a GEF, it has been shown to enhance Vav-induced guanine nucleotide exchange of Rac. However, DOCK180 reportedly is not expressed in blood cells (Hasegawa et al., 1996) and, thus, may not play a role in cytokine activation of Rac in hematopoietic cells.
The present studies have indicated that the Epo-or IL-3-induced activation of Rac may play a role in the signal transduction pathway leading to activation of Erk and Elk-1. However, transient expression of the activated Rac12V mutant did not induce a constitutive activation of Erk (Figure 5a ), thus suggesting that Rac activation alone is not sucient to active Erk. In contrast to the remarkable inhibitory eect of Rac17N on Erk activation, the PI3K inhibitor LY294002 inhibited only the very early phase of Erk activation while inhibiting Rac activation signi®cantly (Figure 4) . The apparent discrepancy may be explained by the inhibitory eect of Akt, the other downstream eector of PI3K, on the cytokine-induced activation of Erk and Elk-1 demonstrated in Figure 6 ; LY294002 inhibits both Rac and Akt, which act downstream of PI3K to play enhancing and inhibitory roles, respectively, in regulation of the Raf/Erk signaling pathway and, therefore, may not have remarkable eects on Erk activation. It is also suggested that the cytokineinduced activation of Rac, which is observed very Figure 6 Akt plays an inhibitory role in activation of the Erk/ Elk-1 signaling pathway. (a) 32D/EpoR-Wt cells or a clone of 32D/EpoR-Wt cells, 32DE/Akt-myr, which constitutively expresses an activated Akt mutant, myr-Akt, were starved from Epo overnight and stimulated with 10 U/ml Epo for indicated times as indicated before solubilization. Total cell lysates were subjected to immunoblotting with an antibody speci®c for the activated form of Erk (aErk-P) followed by reprobing with antiErk (aErk) and anti-Akt (aAkt), as indicated. The positions of myr-Akt and endogenous Akt are indicated. (b) A clone of 32D/ EpoR-Wt cells, 32DE/Tet-Akt-KM, which inducibly expresses a dominant negative Akt mutant, Akt-K179M, when withdrawn from tetracycline, was starved from Epo overnight in medium containing 200 ng/ml tetracycline (Tet+) or without tetracycline (Tet-), as indicated. The position of Akt-K179M (Akt-KM) and endogenous Akt (Akt) is indicated. (c) 32D/EpoR-Wt cells were transiently transfected with 25 mg of pUSE-myr-Akt1 (myr-Akt) or pUSE-Akt1-K179M (Akt-KM), as indicated, along with 0.01 mg of pRL-SV40, 2 mg of pFA-Elk-1, and 20 mg of pFRLuc. After overnight starvation, cells were incubated for 5 h in medium supplemented with 10 U/ml of Epo (Epo) or left untreated with cytokines (7), as indicated, and harvested for the dual-luciferase assay rapidly and transiently, may play a role particularly important in the early phase of Erk activation, which is most signi®cantly inhibited by LY294002.
The strength and duration of Erk activation are important determinants that govern the biological responses to particular stimuli (Bar-Sagi and Hall, 2000) . In addition, down-regulation of Erk signaling pathway has been shown to play an essential role in Epo-induced erythroid dierentiation in a Friend murine leukemia cell line, SKT6 (Matsuzaki et al., 2000) . Therefore, the signaling mechanisms that exist downstream of PI3K to modulate the cytokine-induced activation of Erk may play important biological roles and need to be explored in future studies. A reasonable possibility is that the enhancement of Erk activation by Rac is mediated by the downstream eector PAK1, which has been shown to phosphorylate MEK1 on S298, a site important for binding to Raf-1 to MEK1 (Frost et al., 1997) . In addition, PAK3 has recently been shown to phosphorylate Raf-1 on S338, one of the sites whose phosphorylation is required for activation (King et al., 1998) . In accordance with this, our preliminary experiments have shown that Epo as well as IL-3 induces phosphorylation of Raf-1 on S338, which is inhibited by the PI3K inhibitor LY294002 (A Arai, Z Jin, E Kanda, and O Miura, unpublished results). On the other hand, the inhibitory eect of Akt on Erk activation is most likely explained by a recent observation that Akt suppresses Raf-1 activity by inducing phosphorylation of S259 (Zimmermann and Moelling, 1999) . However, it should be noted that Akt has been reported to phosphorylate Rac (Kwon et al., 2000) , which raises a possibility that Akt may directly aect the activity of Rac or its eects on downstream eectors. The exact mechanisms by which Rac and Akt regulate the Erk/Elk-1 activation pathway downstream of the receptors for Epo and IL-3 are currently under study in our laboratory.
Rac de®cient mice are embryonic lethal because of developmental arrest and cell death of newly generated embryonic mesodermal cells during gastrulation (Sugihara et al., 1998) . Therefore, the physiological signi®cance of Rac on hematopoiesis remains to be determined. However, previous reports have implicated Rac in signaling from the IL-3 receptor as well as in regulation of growth and apoptosis of hematopoietic cells. Romanova et al. (1999) reported that IL-3 induces in IL-3-dependent BaF3 cells the formation of membrane rues, which was also induced by the expression of an activated Rac mutant and was abrogated by that of the dominant negative Rac17N mutant. It was thus suggested that IL-3 activates Rac to induce the membrane rue formation, which is well known to be induced by activated Rac in Swiss 3T3 cells (Bishop and Hall, 2000; Takai et al., 2001) . IL-3 was also reported to activate in IL-3 dependent FL5.12 cells the Rac eector PAK1, which was demonstrated to phosphorylate Bad and to protect cells from apoptosis (Schurmann et al., 2000) . In addition, the activated Rac12V mutant was reported to protect IL-3-deprived BaF3 cells from apoptosis (Nishida et al., 1999) , while the dominant negative Rac17N mutant reduced the proliferative and invasive potentials of 32D cells expressing the BCR/ABL chimeric kinase involved in leukemogenesis of chronic myelogenous leukemia (Skorski et al., 1998) . Furthermore, using the Rac2-D57N mutant, which inhibits both endogenous Rac and Rac2 when expressed in primary murine bone marrow cells, Gu et al. (2001) demonstrated that the de®ciency of Rac and Rac2 leads to increased apoptosis, while overexpression of Rac or its activated mutant leads to increased proliferation. Together, these studies strongly support the idea that Rac plays important roles in antiapoptotic signaling and in regulation of various cellular functions in hematopoietic cells. However, in none of these studies, the eects of hematopoietic cytokines, which play the most important role in regulation of hematopoiesis, on the activity of endogenous Rac have been examined. Furthermore, Geijsen et al. (1999) reported that granulocyte-macrophage colony-stimulating factor, a hematopoietic cytokine that shares the bc receptor chain and the downstream signaling components with IL-3, failed to activate Rac in dierentiated neutrophils. Therefore, the involvement of Rac in hematopoietic cytokine signaling remained elusive. In the present studies, however, we have directly demonstrated that Epo as well as IL-3 activates Rac in hematopoietic cells. The discrepancy between our results Geijsen et al. (1999) is most likely explained by the dierences in dierentiation status of cells examined. Taken together with the previous reports that implicate Rac in regulation of hematopoiesis (Gu et al., 2001; Nishida et al., 1999; Romanova et al., 1999; Schurmann et al., 2000; Skorski et al., 1998) , the present study strongly supports the idea that Rac plays an important role in cytokine receptor signaling regulating the hematopoietic cell growth and functions. Further studies on signaling downstream of Rac will be required to elucidate the molecular mechanisms responsible for these eects.
Materials and methods
Cells and reagents
A clone of IL-3-dependent 32D cells expressing the wild-type murine Epo receptor (EpoR), 32D/EpoR-Wt, was previously described (Miura et al., 1993) and maintained in RPMI 1640 medium supplemented with 10% fetal calf serum and 1 U/ml human recombinant Epo. 32DE/TA cells, which inducibly express the tetracycline transactivator (tTA) when withdrawn from tetracycline, and 32DE/Tet-CrkL or 32DE/Tet-C3G cells, which inducibly overexpress CrkL or C3G, respectively, when withdrawn from tetracycline, were also described previously . A human leukemic cell line expressing the endogenous EpoR, UT-7 (Komatsu et al., 1991) , was kindly provided by Dr Norio Komatsu (Jichi Medical School, Tochigi, Japan).
Recombinant human Epo was kindly provided by Chugai Pharmaceutical Co. Ltd. (Tokyo, Japan). Recombinant murine IL-3 was purchased from PeproTech Inc. (Rocky Hill, NJ, USA). LY294002 was purchased from Calbiochem (La Jolla, CA, USA). Monoclonal antibodies against Rac and phosphotyrosine (4G10) as well as a rabbit polyclonal antibody against Erk were purchased from Upstate Biotechnology (Lake Placid, NY, USA). A monoclonal pan-Ras antibody (Ras 10) was purchased from Calbiochem (La Jolla, CA, USA). Anti-phospho-Erk (Thr202/Tyr204), anti-phospho-Akt (Ser473), and anti-Akt polyclonal antibodies were purchased from New England Biolabs (Beverly, MA, USA). Polyclonal antibodies against Rac2, CrkL, and C3G were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). A mouse monoclonal antibody against the in¯uenza virus hemagglutinin (HA) epitope, used for immunoblotting, and an immobilized anti-HA high anity rat monoclonal antibody, used for immunoprecipitation, were purchased from Roche Molecular Biochemicals (Indianapolis, IN, USA).
Plasmids
Expression plasmids for activated and dominant negative mutants of Rac, pSR_-myc-RacV12 and pSR_-mycRacN17 (Takaishi et al., 1997) , respectively, were kindly provided by Dr Yoshimi Takai (Osaka University, Osaka, Japan). An expression plasmid for HA-tagged ERK2 (S3H-ERK2) was kindly provided by Dr Michael Karin (University of California at San Diego). The pGEX-PAK2-RBD plasmid (Akasaki et al., 1999 ) encoding a glutathione S-transferase (GST) fusion protein containing the Rac binding domain of PAK2 (GST-PAK2-RBD) was kindly provided by Dr Hideki Sumimoto (Kyushu University, Fukuoka, Japan). Expression plasmids for dominant negative mutants of Raf-1 (pcDNA-Raf-dSE) and H-Ras (pcDNA-Ha-Ras17N) as well as that for an activated mutant of H-Ras (pcDNA-Ha-Ras61L) have been described previously Nosaka et al., 1999) . Expression plasmids for dominant negative and activated mutants of Akt, pUSE-Akt1-K179M and pUSE-myr-Akt1, respectively, were purchased from Upstate Biotechnology. Tetracycline responsive expression plasmids for H-Ras61L (pTet-H-Ras61L), H-Ras17N (pTet-H-Ras17N), and Akt-K179M (pTet-Akt1-K179M) were constructed by subcloning the inserts coding for these mutants in the pcDNA and pUSE plasmids into pTet-Splice (GIBCO-BRL, Gaithersburg, MD, USA).
The PathDetect in vivo reporting system for Elk-1, which consists of the pFA-Elk plasmid, encoding the fusion protein consisting of the DNA binding domain of yeast GAL4 and the activation domain of Elk-1, and the pFR-luc plasmid, in which expression of luciferase is controlled by a promoter containing the GAL4-binding sites, was purchased from Stratagene (La Jolla, CA, USA). A control Renilla luciferase plasmid, pRL-SV40, was purchased from Promega (Madison, WI, USA).
Transfection
Transfection for stable expression was carried out essentially as described previously (Miura et al., 1993) . In brief, 32DE/ TA cells were transfected with 10 mg of pTet-H-Ras61L, pTet-H-Ras17N, or pTet-Akt1-K179M along with 1 mg of pMAM2-BSD, purchased from Funakoshi (Tokyo, Japan), by electroporation at 960 mF and 300 V using Gene Pulser apparatus (BioRad, Hercules, CA, USA), followed by selection in medium containing blasticidin-S (Funakoshi) and 500 ng/ml tetracycline. Six clones were isolated by limiting dilution for each transfection and the clones inducibly expressing the highest levels of H-Ras61L (32DE/ Tet-Ras61L), H-Ras17N (32DE/Tet-Ras17N), and Akt-K179M (32DE/Tet-Akt-KM) were selected for subsequent studies. Similarly, a clone of 32D/EpoR-Wt, 32DE/Akt-myr, that constitutively expresses the activated mutant myr-Akt was obtained by transfection of pUSE-myr-Akt1 into 32D/ EpoR-Wt.
For transient expression in 32D/EpoR-Wt cells, 2610 7 cells were electroporated at 960 mF and 280 V with indicated plasmids, essentially as described previously (Miura et al., 1993) . After overnight starvation from Epo, transfected cells were subjected to luciferase reporter assays or immunoprecipitation followed by immunoblotting.
Luciferase reporter assays
Luciferase reporter assays of transiently transfected cells were performed essentially as described previously (Chin et al., 1998) . In brief, 32D/EpoR-Wt cells were electroporated with indicated plasmids and starved overnight in medium without Epo. Cells were then incubated for 5 h in medium with or without cytokines, as indicated, and harvested for the luciferase assay using Dual-Luciferase Reporter Assay System (Promega) according to the manufacturer's instructions. Total amounts of plasmids transfected were adjusted to be constant in each experiment by adding an empty vector plasmid. The luciferase activity was normalized by the Renilla luciferase activity and expressed in arbitrary units.
Immunoprecipitation and GTPases activation assays
For immunoprecipitation experiments, cells were lysed in a lysis buer containing 1% Triton X-100, 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM sodium orthovanadate, 1 mM phenylmethylsulfonyl¯uoride, and 10 mg/ml each of aprotinin and leupeptin. Cell lysates were subjected to immunoprecipitation as described previously (Miura et al., 1994b) . For immunoblot analysis of total cell lysates, samples were prepared by mixing an aliquot of cell lysates with an equal volume of 26Laemmli's sample buer and heating at 1008C for 5 min.
Rac activation in cells was examined by using an activation speci®c probe, GST-PAK2-RBD, as described previously (Nosaka et al., 2001) . In brief, cells were lysed on ice for 1 min in a lysis buer containing 1% Nonidet P-40, 0.25% sodium deoxycholate, 25 mM HEPES (pH 7.5), 150 mM NaCl, 10 mM MgCl 2 , 1 mM sodium orthovanadate, 10% glycerol, 1 mM phenylmethylsulfonyl¯uoride, and 10 mg/ml each of aprotinin and leupeptin. After clari®cation by centrifugation at 15 000 r.p.m. for 1 min at 48C, cell lysates were incubated with the GST-PAK2-RBD fusion protein precoupled to glutathione-agarose beads. After incubation for 30 min at 48C, beads were washed three times in lysis buer. Rac-GTP bound to beads was eluted by heating at 1008C for 5 min in 16Laemmli's sample buer and detected by immunoblotting with anti-Rac. All Rac activation assays were performed at least three times with reproducible results. Similarly, activation of Ras was examined using the GSTRaf-RBD protein as an activation speci®c probe as described previously . Van Aelst L and D'Souza-Schorey C. (1997 
